Neoantigen Vaccines Pass the Immunogenicity Test

Trends Mol Med. 2017 Oct;23(10):869-871. doi: 10.1016/j.molmed.2017.08.007. Epub 2017 Aug 31.

Abstract

Neoantigens arising from tumor-specific genomic alterations constitute authentic non-self antigens and represent a new class of targets for cancer immunotherapy. Recent reports on various vaccine platforms targeting neoantigens suggest a basis for precision therapies customized to each patient's tumor mutational profile.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Antigens, Neoplasm* / immunology
  • Antigens, Neoplasm* / therapeutic use
  • Cancer Vaccines* / immunology
  • Cancer Vaccines* / therapeutic use
  • Humans
  • Immunogenicity, Vaccine*
  • Immunotherapy*
  • Neoplasms* / immunology
  • Neoplasms* / pathology
  • Neoplasms* / therapy

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines